Science and Research

Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda (pembrolizumab) in metastatic non-squamous NSCLC (Samsung SB27-3004)

A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%

Study details
Study-ID: NCT06348199, 2023-507448-36-00
Study-ID: NCT06348199, 2023-507448-36-00
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: DZL, Externally - industry
Funding: DZL, Externally - industry
DZL Participating Sites: UGMLC
DZL Participating Sites: UGMLC
Start Date: 12.03.2024
Completion Date: 30.09.2026
Status: Active / not recruiting
Status: Active / not recruiting
DZL recruiting center
Link to Study


close
chevron-down

Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.